Blinatumomab with lower-dose chemo for B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 59 years old.
- You have been newly diagnosed with a type of leukemia called B-cell acute lymphoblastic leukemia (B-ALL) and you do not have the Philadelphia chromosome.
- You are able to do most of your daily activities (score 0-2 on the ECOG scale).
- Your heart, lungs, liver, and kidneys are working well enough to safely receive the study drugs.
- You do not have leukemia that has spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a lower dose of chemotherapy followed by 14 days of blinatumomab for adults newly diagnosed with a type of leukemia called B-ALL. The goal is to see if this approach works well and reduces side effects.
Hear when a new Precursor B-Cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.